RUNX1 and breast carcinoma: Interestingly, aberrantly high levels of EVI1 have also been observed across a range of non-hematologic malignancies including ovarian cancer,43,44 breast cancer,45 pancreatic cancer,46 colorectal cancer,47 and prostate cancer.48 While transcription factors like EVI1 might have cell type-specific targets and functions resulting from a context-dependent remodeling of the epigenetic landscape and gene expression, it would be of interest to investigate the commonalities in the mechanism of action of EVI1 across these diverse cancer entities.